Medytox said Monday that it has recruited legal experts Lee Doo-sik as its new vice president to put an early end to the ongoing legal battle over its botulinum toxin products. 

On Dec. 22, the Ministry of Food and Drug Safety said it would take administrative steps to suspend the manufacture, sale, and use of Medytox's wrinkle treatment, Innotox, and canceled the approval. The ministry judged Medytox had sold Meditoxin and Coretox without permission and revoked the two drugs' permit.

In response to the regulatory disposition, the company filed a complaint about suspension and cancellation of execution, and the Daejeon District Court temporarily revoked the effect of the administrative measure. The ministry appealed immediately, but the court dismissed it and raised Medytox’s hand.

If the ministry appeals again, the Supreme Court will decide whether to kick out Meditoxin and Coretox from the market.

An official of Medytox says that the company can distribute Meditoxin and Coretox until the results of the case come out.

The official added that Meditoxin and Coretox are still available in the market. He noted that even if the ministry files a complaint again, the company will win, saying that the top court had granted an injunction as requested by businesses on two occasions.

"The recruitment of Vice President Lee is expected to elevate our ethical management system to a global level,” the Medytox official said. “We will also speed up the process to put an early end to the ongoing litigations."

Lee served as the chief of the Seoul Central District Prosecutors' Office and a lawyer at Kim & Chang, the nation’s largest law firm.